MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$109,635K
Proceeds from employee
stock purchase plan...
$811K
Net cash provided by
financing activities
$110,446K
Net increase
(decrease) in cash, cash...
-$24,885K
Canceled cashflow
$110,446K
Stock-based compensation
expense
$6,302K
Non-cash lease expense
-$4,483K
Depreciation and
amortization
$1,230K
Accounts receivable
-$1,090K
Impairment loss on
machinery and equipment
-$402K
Accounts payable
$221K
Amortization of intangible
assets
$146K
Maturities of short term
investments
$133,000K
Net cash used in
operating activities
-$75,587K
Canceled cashflow
$13,874K
Net cash provided by
(used in) investing...
-$59,744K
Canceled cashflow
$133,000K
Deferred revenue
-$65,596K
Net income (loss)
-$17,368K
Accrued liabilities and
other long-term...
-$3,049K
Accretion of discounts on
short-term investments
$2,206K
Prepaid expenses and
other assets
$1,242K
Purchases of short term
investments
$192,524K
Purchases of property and
equipment
$220K
Back
Back
Cash Flow
source: myfinsight.com
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)